Charlotte Shackelford, PA
Physician Assistant · Purcell, OKNPI 1366601015
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 462 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 462 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$984
- AstraZeneca$946
- Lilly USA, LLC$898
- Pfizer$694
- AbbVie$637
- GSK$476
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,79799%
- Education$731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $984 |
| AstraZeneca | 48 | $946 |
| Lilly USA, LLC | 57 | $898 |
| Pfizer | 50 | $694 |
| AbbVie | 40 | $637 |
| GSK | 39 | $476 |
| Amgen | 25 | $409 |
| Boehringer Ingelheim | 20 | $405 |
| Sanofi-aventis U.S. LLC | 21 | $390 |
| Bayer | 23 | $356 |
| Astellas Pharma US Inc | 10 | $236 |
| Sumitomo Pharma America, Inc. | 10 | $183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $171 |
| Merck | 11 | $164 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $148 |
| Mylan Specialty L.p. | 5 | $110 |
| Novartis | 6 | $109 |
| Teva Pharmaceuticals USA, Inc. | 6 | $107 |
| Exact Sciences | 6 | $100 |
| Halozyme Inc | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Viatris Specialty LLC | 2 | $33 |
| Mayne Pharma Commercial LLC | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Edwards Lifesciences | 1 | $23 |
| Lundbeck LLC | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Alvogen Inc | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$7,870 in reported general payments places this provider in the 95th percentile of 1,491 physician assistant providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $175,538 |
| JardianceEmpagliflozin | 100 | $129,006 |
| EliquisApixaban | 96 | $85,814 |
| TrulicityDulaglutide | 59 | $75,247 |
| FarxigaDapagliflozin Propanediol | 70 | $65,108 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $60,298 |
| MounjaroTirzepatide | 31 | $56,816 |
| XareltoRivaroxaban | 30 | $38,968 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $30,367 |
| MyrbetriqMirabegron | 28 | $23,403 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $19,378 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $15,555 |
| LinzessLinaclotide | 13 | $10,481 |
| Atorvastatin Calcium | 401 | $5,702 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 125 | $3,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $984 | $175,538126 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $898 | $132,06390 claims |
| Boehringer IngelheimJardiance | $405 | $129,006100 claims |
| PfizerEliquis | $694 | $85,81496 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $946 | $80,66294 claims |
| GSKTrelegy Ellipta | $476 | $60,29861 claims |
| Astellas Pharma US IncMyrbetriq | $236 | $23,40328 claims |
| AbbVieLinzess, Synthroid | $637 | $11,93332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,491 physician assistant providers in Oklahoma.
Other physician assistant in Purcell
- Timara StellingPurcell$8K
- Eric CampbellEdmond$246K
- Jennifer SmithOklahoma City$134K
- Christy NiehuesMustang$28K
- Matthew PattonTulsa$24K
- Sarah HawkOklahoma City$23K
- Gavin ChristieEdmond$19K
- Michelle GreenTulsa$18K
- Muge ParkTulsa$17K
- Rose RamirezTulsa$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.